Boston Biomedical Innovation Center (B-BIC) is a life sciences accelerator funded by the National Institutes of Health and our member institutions to increase the return on investment in research. We speed the translation of research technologies into products for doctors and their patients, for the good of society.
Our members are a consortium of academic medical centers in Boston including Brigham and Women’s Hospital, Harvard Medical School, Massachusetts General Hospital, and the Massachusetts Institute of Technology.
B-BIC provides funding for technology development and translational research, including regulatory, reimbursement, and business development aspects that are part of an overall commercialization strategy.
RECIPIENT: Dr. Ehud Schmidt TITLE: An MRI-Compatible Voltage Device Tracking For Multimodality Electrophysiology TYPE OF AWARD: PILOT INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Ehud Schmidt, PhD, Director of Engineering Physics in the Department of Radiology, Brigham and Women’s Hospital, and Associate Professor at Harvard Medical School receives a Pilot award to develop MRI-compatible voltage device tracking for multimodality…Read More
RECIPIENT: Dr. Warren Zapol TITLE: Portable and Affordable Lightweight NO Generator TYPE OF AWARD: DRIVE INSTITUTION: MGH DESCRIPTION: Warren Zapol, MD, Director of the MGH Anesthesia Center for Critical Care Research at Massachusetts General Hospital, receives a DRIVE award to develop electric nitric oxide generation for medical purposes. Inhaled nitric oxide (NO) was approved by the FDA…Read More
RECIPIENT: Dr. Jonghan Kim TITLE: Hydrogel-based nanochelator therapy for iron overload disorders TYPE OF AWARD: Drive TECHNOLOGY TYPE: Small Molecule CLINICAL AREA: Blood INSTITUTION: Northeastern & MGH DESCRIPTION: Iron overload, best represented by hereditary hemochromatosis (primary/genetic iron overload) and transfusional hemoglobinopathy (secondary/acquired iron overload), is a well-defined risk factor for several critical diseases, including heart failure, liver cirrhosis, arthritis,…Read More
Q: Do I need to have slides? A: Pitches only need to address the suggested elements. Use of reference materials or other visual elements is welcome if they help convey the product concept and can be shared using your laptop screen. AV equipment will not be available. Q: How formal will the pitches be? A:…Read More
Keep pitch short and focused on the technology and its commercial application. Limit the discussion of preliminary results, and focus on the most relevant results with conclusions – not data. Present the science within the context of the business strategy. FAST PITCH FOR FUNDING is Monday, March 5 at 2:00pm at the MASS GENERAL RESEARCH INSTITUTE, SIMCHES RESEARCH BUILDING, 185…Read More
RECIPIENT: Dr. J. Brian McAlvin TITLE: A Novel Method To Treat The Systemic Inflammatory Response Syndrome (SIRS) TYPE OF AWARD: Pilot TECHNOLOGY TYPE: Therapeutic Device CLINICAL AREA: Blood INSTITUTION: Boston Children’s Hospital DESCRIPTION: We have developed highly-selective blood-filtering devices that are capable of filtering of individual, harmful molecules from the blood of patients rendered critically ill by the…Read More
ARE YOU THINKING ABOUT COMMERCIALIZING YOUR RESEARCH? Fast Pitch for Funding is an event hosted by the Boston Biomedical Innovation Center, that provides you the opportunity to pitch a team of experts on your research. You will receive immediate feedback with the opportunity to apply for our grant programs which can provide up to $350,000…Read More
RECIPIENT: Dr. Sylvie Breton TITLE: Predicting and Preventing Acute Kidney Injury Associated with Cardiovascular Diseases TYPE OF AWARD: PILOT TECHNOLOGY TYPE: Small Molecule Drug CLINICAL AREA: Heart INDICATION: Acute Kidney Injury INSTITUTION: MGH DESCRIPTION: Acute kidney injury (AKI) is a frequent complication of hospitalized patients. Unfortunately, there is no cure for this potentially deadly condition. Thus, a critical…Read More
RECIPIENT: Dr. Nelson Ruiz – Opazo TITLE: Fully humanized anti-DEpR antibody therapy for acute lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) TYPE OF AWARD: PILOT TECHNOLOGY TYPE: Biologic Drug CLINICAL AREA: Lung INDICATION: Acute Lung Injury / Acute Respiratory Distress Syndrome INSTITUTION: Boston University DESCRIPTION:The feed-forward progression of acute lung injury (ALI) towards acute respiratory distress syndrome (ARDS)…Read More
RECIPIENT: Dr. Leo Tsai TITLE: A Novel Coaxial Deflectable Microcatheter for Rapid Navigation of Tortuous Vessels TYPE OF AWARD: DRIVE INSTITUTION: Beth Israel Deaconess Medical Center TECHNOLOGY TYPE: Therapeutic Device DESCRIPTION: Microcatheters are used to access small vessels throughout the body to treat a wide variety of pathology, from traumatic hemorrhage to tumors. Selection of…Read More
RECIPIENT: Dr. Pamela Silver TITLE: A Targeted Erythropoietin-Based Therapeutic TYPE OF AWARD: DRIVE INSTITUTION: Harvard Medical School DESCRIPTION: Pamela Silver, PhD., Elliot T and Onie H Adams Professor of Biochemistry and Systems Biology, Harvard Medical School, and a founding member of the Wyss Institute was awarded a DRIVE grant for continued development of a targeted erythropoietin-based therapeutic. EPO plays…Read More
RECIPIENT: Dr. Ben Matthews TITLE: PR1P, an inhaled novel short peptide for emphysema TYPE OF AWARD: PILOT INSTITUTION: Boston Children’s Hospital DESCRIPTION: Emphysema is a chronic progressive pulmonary disease characterized by destruction of alveoli leading to impaired lung function that threatens human health worldwide. Disease progression is due in part to dysregulation of the survival factor Vascular Endothelial Growth Factor (VEGF). …Read More
RECIPIENT: Dr. Jill Goldstein TITLE: Development of an electroceutical for treatment of comorbidity between hypertension and major depression. TYPE OF AWARD: DRIVE INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Hypertension is a leading cause of morbidity and mortality in the United States with an overall prevalence of approximately 29%, corresponding to 70 million of Americans. Despite the benefits…Read More
RECIPIENT: Dr. Paul Yu TITLE: Molecular Imaging of Dysregulated Angiogenesis in Pulmonary Arterial Hypertension TYPE OF AWARD: DRIVE INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Pulmonary arterial hypertension (PAH) is a disorder of elevated pulmonary vascular resistance characterized by progressive remodeling and obliteration of resistance-determining vessels of the pulmonary circulation. Despite current therapies, transplant-free survival…Read More